Muna Therapeutics

Muna Therapeutics is a private, preclinical-stage biotech founded in 2020, targeting high-unmet-need neurodegenerative diseases with small molecule drugs. The company leverages a team with deep neurology drug discovery experience and is supported by world-class scientific founders and advisors. Its core mission is to develop disease-modifying therapies that alter the course of Alzheimer's and Parkinson's diseases, representing a significant market opportunity.

Small molecule discovery platform focused on inducing resilience in the brain to treat neurodegeneration. Likely involves target identification/validation and drug design for neuroprotective pathways.

Muna operates in a highly competitive space dominated by large pharmaceutical companies and numerous biotechs, all seeking disease-modifying treatments for Alzheimer's and Parkinson's. Competition includes both small molecule and biologic approaches (e.g., antibodies). Success will require a differentiated mechanism or superior efficacy/safety profile.